Crinetics Pharmaceuticals IncNASDAQ:CRNX
- LAST PRICE46.6300
- TODAY'S CHANGE (%)-0.8400 (-1.7695%)
- Bid / Lots46.5400/ 4
- Ask / Lots46.6300/ 2
- Open / Previous Close48.0100 / 47.4700
- Day Range
- 52 Week Range
- Volume351,541
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRNX |
|---|---|---|
| 09:32 ET | 4330 | 48.24 |
| 09:36 ET | 400 | 48.12 |
| 09:39 ET | 100 | 47.97 |
| 09:41 ET | 1300 | 47.66 |
| 09:43 ET | 129 | 47.5579 |
| 09:45 ET | 374 | 47.74 |
| 09:52 ET | 100 | 47.815 |
| 09:54 ET | 1806 | 47.67 |
| 09:56 ET | 406 | 47.44 |
| 09:57 ET | 100 | 47.44 |
| 09:59 ET | 1356 | 47.25 |
| 10:01 ET | 400 | 47.105 |
| 10:06 ET | 1200 | 46.99 |
| 10:08 ET | 1415 | 47.045 |
| 10:10 ET | 545 | 47.2 |
| 10:12 ET | 100 | 47.185 |
| 10:14 ET | 200 | 47.195 |
| 10:15 ET | 200 | 47.215 |
| 10:17 ET | 800 | 47.31 |
| 10:21 ET | 476 | 47.3 |
| 10:24 ET | 2400 | 47.34 |
| 10:26 ET | 5899 | 47.395 |
| 10:28 ET | 6735 | 47.44 |
| 10:30 ET | 2600 | 47.52 |
| 10:32 ET | 1981 | 47.43 |
| 10:33 ET | 1174 | 47.505 |
| 10:35 ET | 3119 | 47.645 |
| 10:37 ET | 1000 | 47.625 |
| 10:39 ET | 1000 | 47.485 |
| 10:42 ET | 2066 | 47.455 |
| 10:44 ET | 600 | 47.475 |
| 10:46 ET | 500 | 47.585 |
| 10:48 ET | 100 | 47.585 |
| 10:50 ET | 374 | 47.59 |
| 10:53 ET | 800 | 47.51 |
| 10:55 ET | 3132 | 47.43 |
| 10:57 ET | 136 | 47.42 |
| 11:00 ET | 400 | 47.48 |
| 11:02 ET | 3093 | 47.46 |
| 11:04 ET | 8900 | 47.35 |
| 11:08 ET | 1378 | 47.35 |
| 11:09 ET | 1400 | 47.45 |
| 11:11 ET | 100 | 47.4 |
| 11:13 ET | 900 | 47.43 |
| 11:15 ET | 983 | 47.58 |
| 11:18 ET | 325 | 47.52 |
| 11:20 ET | 689 | 47.545 |
| 11:22 ET | 2015 | 47.475 |
| 11:24 ET | 100 | 47.405 |
| 11:27 ET | 490 | 47.47 |
| 11:29 ET | 2600 | 47.45 |
| 11:31 ET | 800 | 47.46 |
| 11:33 ET | 1100 | 47.48 |
| 11:36 ET | 400 | 47.41 |
| 11:38 ET | 1800 | 47.31 |
| 11:40 ET | 696 | 47.37 |
| 11:42 ET | 100 | 47.355 |
| 11:44 ET | 100 | 47.355 |
| 11:45 ET | 1400 | 47.31 |
| 11:47 ET | 16084 | 47.15 |
| 11:49 ET | 728 | 47.035 |
| 11:51 ET | 1260 | 47.085 |
| 11:56 ET | 500 | 47.04 |
| 11:58 ET | 200 | 47.04 |
| 12:00 ET | 400 | 47.055 |
| 12:02 ET | 6446 | 47.18 |
| 12:03 ET | 876 | 47.14 |
| 12:05 ET | 2700 | 47.03 |
| 12:07 ET | 9379 | 47.21 |
| 12:09 ET | 1249 | 47.17 |
| 12:14 ET | 2312 | 47.37 |
| 12:16 ET | 7076 | 47.37 |
| 12:18 ET | 3120 | 47.31 |
| 12:20 ET | 3854 | 47.35 |
| 12:21 ET | 5477 | 47.34 |
| 12:23 ET | 1650 | 47.405 |
| 12:25 ET | 13388 | 47.6892 |
| 12:27 ET | 6185 | 47.6788 |
| 12:30 ET | 4900 | 47.4933 |
| 12:32 ET | 12313 | 47.395 |
| 12:34 ET | 5608 | 47.3 |
| 12:36 ET | 20906 | 47.15 |
| 12:38 ET | 703 | 47.36 |
| 12:39 ET | 1100 | 47.37 |
| 12:41 ET | 2500 | 47.33 |
| 12:43 ET | 500 | 47.31 |
| 12:45 ET | 2456 | 47.315 |
| 12:48 ET | 5900 | 47.485 |
| 12:50 ET | 1000 | 47.5 |
| 12:52 ET | 2570 | 47.525 |
| 12:54 ET | 700 | 47.56 |
| 12:56 ET | 1346 | 47.57 |
| 12:57 ET | 6105 | 47.4699 |
| 12:59 ET | 290 | 47.405 |
| 01:01 ET | 1300 | 47.33 |
| 01:03 ET | 1149 | 47.235 |
| 01:10 ET | 1405 | 47.275 |
| 01:12 ET | 100 | 47.32 |
| 01:15 ET | 1100 | 47.31 |
| 01:17 ET | 100 | 47.32 |
| 01:19 ET | 200 | 47.32 |
| 01:21 ET | 1500 | 47.21 |
| 01:24 ET | 1954 | 47.125 |
| 01:26 ET | 100 | 47.125 |
| 01:28 ET | 736 | 47.13 |
| 01:30 ET | 101 | 47.135 |
| 01:32 ET | 1701 | 47.1 |
| 01:33 ET | 1663 | 47.16 |
| 01:42 ET | 4230 | 47.2108 |
| 01:44 ET | 777 | 47.21 |
| 01:46 ET | 100 | 47.165 |
| 01:48 ET | 2865 | 47.125 |
| 01:50 ET | 100 | 47.125 |
| 01:51 ET | 3191 | 46.98 |
| 01:53 ET | 1953 | 46.86 |
| 01:55 ET | 700 | 46.795 |
| 02:00 ET | 400 | 46.77 |
| 02:02 ET | 1000 | 46.645 |
| 02:04 ET | 950 | 46.53 |
| 02:06 ET | 400 | 46.63 |
May 23, 2024
DJ Crinetics Pharmaceuticals Is Maintained at Outperform by Baird, from 12:48PM ET on Thursday May 23, 2024 by Dow Jones
12:48PM ET on Thursday May 23, 2024 by Dow JonesDJ Crinetics Pharmaceuticals Is Maintained at Overweight by Morgan Stanley, from 11:33AM ET on Thursday May 23, 2024 by Dow Jones
11:33AM ET on Thursday May 23, 2024 by Dow JonesDJ Crinetics Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 7:25AM ET on Thursday May 23, 2024 by Dow Jones
7:25AM ET on Thursday May 23, 2024 by Dow Jones
May 22, 2024
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts, from 8:00AM ET on Wednesday May 22, 2024 by Dow Jones
8:00AM ET on Wednesday May 22, 2024 by Dow Jones
May 14, 2024
DJ Crinetics Pharmaceuticals Price Target Maintained With a $65.00/Share by Cantor Fitzgerald, from 8:55AM ET on Tuesday May 14, 2024 by Dow Jones
8:55AM ET on Tuesday May 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Crinetics Pharmaceuticals Inc | 3.7B | -12.4x | --- |
Merus NV | 3.5B | -19.5x | --- |
Immunovant Inc | 4.2B | -15.5x | --- |
Biohaven Ltd | 3.2B | -5.5x | --- |
SpringWorks Therapeutics Inc | 3.1B | -8.1x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Company Information
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Contact Information
- Headquarters
- 10222 Barnes Canyon Rd Bldg 2SAN DIEGO, CA, United States 92121-2711
- Phone
- 858-450-6464
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Wendell Wierenga
- Co-Founder, Director
- R. Scott Struthers
- Co-Founder, Chief Scientific Officer
- Stephen Betz
- Chief Financial Officer
- Marc Wilson
- Chief Operating Officer
- Jeff Knight
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7B |
|---|---|
Revenue (TTM) | $2.0M |
Shares Outstanding | 78.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.66 |
EPS | $-3.77 |
Book Value | $7.91 |
P/E Ratio | -12.4x |
Price/Sales (TTM) | 1,896.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,571.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
